We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
John
Allotey
-
john.allotey@liverpool.ac.uk
Dr
Carmel
Moore
+44 (0)1245 684938
carmel.moore@aru.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Pregnant women with epilepsy
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Every year in the UK, around 2,500 women with epilepsy get pregnant. Epilepsy is one of the leading causes of maternal death and women with epilepsy face higher risks during pregnancy such as miscarriage, high blood pressure, early birth, and problems with the baby’s growth. During pregnancy, changes in the body can affect seizure patterns and how medicines which help control epilepsy are processed in the body. Some women stop taking their medication on their own because they worry it may harm their baby. These factors can increase the risk of seizures which is why specialist epilepsy care is recommended during pregnancy. However, in practice, many don’t receive specialist care or early enough. For this study, a new programme (the EpiSafe bundle) has been developed, which aims to support more women accessing specialist care during pregnancy and to improve overall health outcomes.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
Unit-level exclusion criteria, maternity units:1. Where there is no access to dedicated epilepsy specialists (either obstetric or neurological)2. That lack the resources to implement the EpiSafe bundle 3. Where procedures are already in place for all women with epilepsy to access specialist epilepsy care <14 weeks' gestation
Individual level exclusion criteria, pregnant women:1. With non-epileptic attack disorder (NEAD)2. Whose epilepsy diagnosis was not confirmed before pregnancy3. Who had already seen or are planning to see an epilepsy specialist in the first trimester 4. Less than 18 years of age5. Withdrawal of consent to use data, through the NHS data opt-out
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Carmel
Moore
+44 (0)1245 684938
carmel.moore@aru.ac.uk
Prof
John
Allotey
-
john.allotey@liverpool.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by University of Liverpool and funded by National Institute for Health and Care Research.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 68695
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
